Mogroside IIIeCAS# 88901-37-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 88901-37-5 | SDF | Download SDF |
| PubChem ID | 102350789 | Appearance | White powder |
| Formula | C48H82O19 | M.Wt | 963.15 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in pyridine | ||
| Chemical Name | (2R,3R,4S,5S,6R)-2-[[(3S,8S,9R,10R,11R,13R,14S,17R)-17-[(2R,5R)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-hydroxy-6-methylheptan-2-yl]-11-hydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol | ||
| SMILES | CC(CCC(C(C)(C)O)OC1C(C(C(C(O1)CO)O)O)OC2C(C(C(C(O2)CO)O)O)O)C3CCC4(C3(CC(C5(C4CC=C6C5CCC(C6(C)C)OC7C(C(C(C(O7)CO)O)O)O)C)O)C)C | ||
| Standard InChIKey | QATISCJMIITVAB-CNEPTXDISA-N | ||
| Standard InChI | InChI=1S/C48H82O19/c1-21(9-13-31(45(4,5)61)66-43-40(37(58)34(55)27(20-51)64-43)67-42-39(60)36(57)33(54)26(19-50)63-42)22-15-16-46(6)28-12-10-23-24(48(28,8)29(52)17-47(22,46)7)11-14-30(44(23,2)3)65-41-38(59)35(56)32(53)25(18-49)62-41/h10,21-22,24-43,49-61H,9,11-20H2,1-8H3/t21-,22-,24-,25-,26-,27-,28+,29-,30+,31-,32-,33-,34-,35+,36+,37+,38-,39-,40-,41+,42+,43+,46+,47-,48+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Mogroside IIIe has anti-inflammatory activity, it attenuates LPS-induced acute lung injury in mice partly through regulation of the TLR4/MAPK/NF-κB axis via AMPK activation. 2. Mogroside IIIe has anti-fibrotic activity, it reduces pulmonary fibrosis through Toll-Like receptor 4 pathways. |
| Targets | TNF-α | IL Receptor | TLR | MAPK | NF-kB | TGF-β/Smad |
Mogroside IIIe Dilution Calculator
Mogroside IIIe Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.0383 mL | 5.1913 mL | 10.3826 mL | 20.7652 mL | 25.9565 mL |
| 5 mM | 0.2077 mL | 1.0383 mL | 2.0765 mL | 4.153 mL | 5.1913 mL |
| 10 mM | 0.1038 mL | 0.5191 mL | 1.0383 mL | 2.0765 mL | 2.5956 mL |
| 50 mM | 0.0208 mL | 0.1038 mL | 0.2077 mL | 0.4153 mL | 0.5191 mL |
| 100 mM | 0.0104 mL | 0.0519 mL | 0.1038 mL | 0.2077 mL | 0.2596 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Mogroside V
Catalog No.:BCN1036
CAS No.:88901-36-4
- Bafilomycin A1
Catalog No.:BCC3914
CAS No.:88899-55-2
- Atrial natriuretic factor (1-28) (rat)
Catalog No.:BCC5843
CAS No.:88898-17-3
- Inulanolide A
Catalog No.:BCN3705
CAS No.:888941-86-4
- Fosinopril sodium
Catalog No.:BCC2141
CAS No.:88889-14-9
- Sprengerinin A
Catalog No.:BCN6658
CAS No.:88866-99-3
- Adrenorphin, Free Acid
Catalog No.:BCC1011
CAS No.:88866-92-6
- Sprengerinin C
Catalog No.:BCN6657
CAS No.:88861-91-0
- 11,12-De(methylenedioxy)danuphylline
Catalog No.:BCN4436
CAS No.:888482-17-5
- Ganetespib (STA-9090)
Catalog No.:BCC2336
CAS No.:888216-25-9
- Galanin (porcine)
Catalog No.:BCC5960
CAS No.:88813-36-9
- Gambogoic acid B
Catalog No.:BCN7936
CAS No.:887923-50-4
- Mogroside IIe
Catalog No.:BCN3168
CAS No.:88901-38-6
- Mogroside IVa
Catalog No.:BCN3165
CAS No.:88901-41-1
- Mogroside III-A1
Catalog No.:BCN3170
CAS No.:88901-42-2
- Mogroside III-A2
Catalog No.:BCN7925
CAS No.:88901-43-3
- Mogroside II-A1
Catalog No.:BCN7926
CAS No.:88901-44-4
- Mogroside II-A2
Catalog No.:BCN3180
CAS No.:88901-45-5
- (-)-Xestospongin C
Catalog No.:BCC7002
CAS No.:88903-69-9
- Mogroside IVe
Catalog No.:BCN3166
CAS No.:88915-64-4
- Mogrol
Catalog No.:BCN8446
CAS No.:88930-15-8
- Dipsanoside A
Catalog No.:BCN2877
CAS No.:889678-62-0
- Dipsanoside B
Catalog No.:BCN2878
CAS No.:889678-64-2
- Quinolinic acid
Catalog No.:BCC6573
CAS No.:89-00-9
Mogroside IIIE, a Novel Anti-Fibrotic Compound, Reduces Pulmonary Fibrosis through Toll-Like Receptor 4 Pathways.[Pubmed:28280123]
J Pharmacol Exp Ther. 2017 May;361(2):268-279.
Idiopathic pulmonary fibrosis is a progressive fibrotic lung disease, and eventually most patients develop respiratory failure with a median survival rate of 2 to 3 years after diagnosis due to the lack of clinically effective therapies. Mogroside IIIe (MGIIIE), a cucurbitane-type compound, was isolated from Siraitia grosvenorii MGIIIE has shown the strongest inhibition of nitric oxide release, a crucial inflammatory factor, from lipopolysaccharide (LPS)-treated RAW264.7 cells compared with other mogrosides. In the pulmonary fibrosis mouse model induced by bleomycin, MGIIIE treatment attenuated pulmonary fibrosis, indicated as a reduction in myeloperoxidase activity, collagen deposition, and pathologic score. MGIIIE also significantly suppressed expression of several important fibrotic markers, e.g., alpha-smooth muscle actin, collagen I, transforming growth factor-beta (TGF-beta) signal, and metalloproteinases-9/tissue inhibitor of metalloproteinase-1. Furthermore, MGIIIE blocked tansdifferentiation of lung resident fibroblasts into myofibroblast-like cells induced by TGF-beta or LPS and subsequently inhibited collagen production in lung fibroblasts. These data indicate that MGIIIE is a potent inhibitor for pulmonary fibrosis. In vitro and in vivo mechanistic studies have shown that MGIIIE significantly decreased expression of toll-like receptor 4 (TLR4) and its downstream signals of myeloid differentiation factor 88 (MyD88)/mitogen-activated protein kinase (MAPK), an inflammatory signal essential for extracellular matrix (ECM) deposition in pulmonary fibroblasts. Taken together, these results demonstrate that MGIIIE significantly prevents pulmonary fibrosis by inhibiting pulmonary inflammation and ECM deposition through regulating TLR4/MyD88-MAPK signaling. Our study suggests that MGIIIE may have therapeutic potential for treating pulmonary fibrosis in clinical settings.
Mogroside IIIE Attenuates LPS-Induced Acute Lung Injury in Mice Partly Through Regulation of the TLR4/MAPK/NF-kappaB Axis via AMPK Activation.[Pubmed:28512854]
Phytother Res. 2017 Jul;31(7):1097-1106.
Acute lung injury (ALI) often leads to high mortality, and there is as yet no effective drug treatment. The present study aimed to investigate protective effects of Mogroside IIIe (MGIIIE, a cucurbitane-type triterpenoid from Siraitia grosvenorii Fruits) in experimental ALI and its underlying mechanism. MGIIIE (1, 10 0r 20 mg/kg) was orally administered for 1 h before a single intratracheal administration of lipopolysaccharide (LPS, 5 mg/kg). MGIIIE treatment dose-dependently suppressed pulmonary oedema, pro-inflammatory mediators (IL-1beta, IL-6, TNF-alpha and HMGB1) release and higher MPO activity in lung tissues induced by LPS challenge. Molecular researches showed that Mogroside IIIe (20 mg/kg) not only increased the phosphorylation of adenosine 5'-monophosphate-activated protein kinase (AMPK) but suppressed the over-expression of toll-like receptor 4 (TLR4) and myeloid differentiation factor 88 (MyD88). In addition, MGIIIE also inhibited the activation of MAPKs and nuclear factor kappaB (NF-kappaB) signalling in lung tissues from LPS-challenged mice. Similar antiinflammatory effects of MGIIIE were obtained in LPS-treated macrophages. Compound C (a pharmacological AMPK inhibitor) obviously reversed the antiinflammatory effect of MGIIIE in LPS-induced ALI mice. Taken together, AMPK activation plays a crucial role in the antiinflammatory effects of MGIIIE in LPS-induced ALI by down-regulating TLR4/MAPK/NF-kappaB signalling pathways. Copyright (c) 2017 John Wiley & Sons, Ltd.
